Evaluation and Validation of Imaging Biomarkers of Tumor Response to Treatment

肿瘤治疗反应的影像生物标志物的评估和验证

• 批准号: 8444704
• 负责人: Thomas E Yankeelov
• 金额: $ 12.1万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2016-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8444704
• 关键词: Acceleration; Animal Model; Animals; Apoptosis; Biological Markers; Blood Vessels; Breast Cancer Treatment; Categories; Clinic; Clinical; Clinical Research; Clinical Trials; Clinical Trials Design; Combined Modality Therapy; Data; Disease; ERBB2 gene; Educational workshop; Evaluation; Goals; Healthcare; Histology; Human; Image; Imaging Techniques; Individual; Institute of Medicine (U.S.); Laboratories; Longitudinal Studies; Magnetic Resonance Imaging; Malignant Neoplasms; Mammary Neoplasms; Mammary Tumorigenesis; Measurement; Measures; Medicine; Methodology; Methods; Metric; Molecular; Monitor; Patient Care; Patients; Physiological; Polyomavirus; Positron-Emission Tomography; Protocols documentation; Reporting; Research; Resistance; Roche brand of trastuzumab; Simulate; Standardization; Stress; Summary Reports; Techniques; Testing; Translations; Validation; Xenograft procedure; annexin A5; anticancer research; base; clinical care; clinically relevant; docetaxel; imaging modality; improved; in vivo; lapatinib; malignant breast neoplasm; molecular/cellular imaging; mouse model; pre-clinical; preclinical study; public health relevance; response; single photon emission computed tomography; treatment effect; treatment response; triple-negative invasive breast carcinoma; tumor; tumor growth; water diffusion

DESCRIPTION (provided by applicant): The aims of the proposed research are to critically evaluate, compare and validate selected multi-modality imaging metrics as quantitative (surrogate) biomarkers of the response of breast tumors to specific treatments to provide the scientific basis for their translation into patient management and clinical trials. Recent years have seen a dramatic increase in the range of information available from imaging methods so that a number of techniques are available to quantitatively monitor tumor growth and treatment response. Several of these have been used in both pre-clinical and clinical studies, but with mixed results confounded by lack of standardization, inadequate understanding of underlying mechanisms and absence of appropriate validation to assist their interpretation. We propose to systematically evaluate emerging, clinically-viable imaging metrics in appropriate animal models to establish which combination of methods is most accurate at predicting response to specific treatments that are relevant for breast cancer. The paradigm we have chosen to achieve these ends considers two major categories of human breast cancer, HER2 positive tumors and ER/PR/HER2 triple-negative tumors and both established and emerging therapies. For each category we will assess treatment response by performing longitudinal studies that combine PET, SPECT, and MRI to provide functional assessments of the response of breast tumors to treatment. We will also correlate imaging with histology data to understand the mechanistic underpinnings of the information provided by each type of measurement. We hypothesize that treatment type will determine which imaging metrics are most sensitive to early response. To test this hypothesis we will pursue the following specific aims: 1. [HER2+ cancer] In the BT-474 mouse model of breast cancer with and without resistance to Herceptin (to simulate responders and nonresponders, respectively), measure the effects of treatment response to Herceptin or Herceptin+lapatinib as reported by PET, SPECT, and MRI metrics. This study will also be performed in the polymoma middle T (PyMT) spontaneous mouse model of human breast cancer. 2. [Triple negative cancer] In the MDA-231 mouse model of triple-negative breast cancer with and without resistance to Docetaxel (to simulate responders and nonresponders, respectively), measure the effects of treatment to Docetaxel or Docetaxel+sunitinib as reported by PET, SPECT, and MRI metrics.

描述（由申请人提供）：拟议的研究的目的是批判性评估，比较和验证选定的多模式成像指标作为乳腺肿瘤对特定治疗的反应的定量（替代）生物标志物，以提供科学基础，以将其转化为患者管理和临床试验。 近年来，成像方法可获得的信息范围急剧增加，因此可以使用许多技术来定量监测肿瘤生长和治疗反应。其中一些已用于临床前和临床研究中，但由于缺乏标准化，对基本机制的理解不足以及缺乏适当的验证以帮助其解释而混淆。我们建议在适当的动物模型中系统地评估新兴的，临床上可行的成像指标，以确定哪种方法的组合最准确，可以预测对与乳腺癌相关的特定治疗方法的反应。我们选择实现这些目的的范式考虑了人类乳腺癌，HER2阳性肿瘤和ER/PR/HER2三阴性肿瘤的两个主要类别，并且都建立和新兴疗法。对于每个类别，我们将通过进行纵向研究来评估治疗反应，该研究结合了PET，SPECT和MRI，以对乳腺肿瘤对治疗的反应进行功能评估。我们还将将成像与组织学数据相关联，以了解每种测量类型提供的信息的机械基础。我们假设处理类型将确定哪些成像指标对早期响应最敏感。为了检验这一假设，我们将追求以下特定目的：1。[HER2+癌症]在BT-474乳腺癌的小鼠模型中，有或没有对Herceptin的抗性（分别模拟反应者和非反应者），衡量治疗对赫赛普蛋白或Herseptin或Hersectein+ Lapatinib的响应的影响，因为PET，Spect，Spect，Spect，Spect，Spect，Spect，Spect，Spect，Spect，Spect，Spect和Mri Mri Meri and Mri Mericrics和Mri Mri Mericrics和Mri Mri Mericrics。这项研究还将在人类乳腺癌的自发小鼠模型中进行。 2。[三重阴性癌]在三阴性乳腺癌的MDA-231小鼠模型中，有或没有对多西他赛的抗性（分别模拟反应者和无反应者），测量对多西他赛或多西他赛或Docetaxel+sunitinib的影响，PET，SPECT SPECT和MRI MERRICS和MRI MERRICS报告。